The discovery of the pathophysiology(ies) for schizophrenia is necessary to direct rational treatment directions for this brain disorder. Firm knowledge about this illness is limited to areas of phenomenology, clinical electrophysiology, and genetic risk; some aspects of dopamine pharmacology, cognitive symptoms, and risk genes are known. Basic questions remain about diagnostic heterogeneity, tissue neurochemistry, and in vivo brain function. It is an illness ripe for molecular characterization using a rational approach with a confirmatory strategy; drug discovery based on knowledge is the only way to advance fully effective treatments. This paper reviews the status of general knowledge in this area and proposes an approach to discovery, including identifying brain regions of dysfunction and subsequent localized, hypothesis-driven molecular screening.
Schizophrenia is a brain disease that has afflicted humans since the beginning of written history. Its distinctive clinical features are easily recognized in early Greek and Hebrew literature, and have not changed remarkably over the millennia. However, the formulation of the presentation has changed during this time reflecting sociopolitical orientations and often nonmedical formulations. During various historical periods, psychotic persons were called prophets or seers; occasionally, manifestations of the devil, sometimes saints; but until modern times, rarely ill. It was not until the last half of the 19th century that compassionate treatment was invoked for the mentally ill. At the turn of the 20th century, schizophrenic psychosis was distinguished from affective psychosis on the basis of outcome. In the early 1930s, schizophrenia was treated with unusual and unlikely procedures such as 'fever therapy,' adrenalectomy, and vasectomy, all tested on speculation, but carried out in response to overwhelming medical need. 1 It was not until the end of World War II that reserpine was used with some efficacy, but with considerable side effect burden. Chlorpromazine was the first effective, selective, oral antipsychotic drug; it was identified without a known tissue target by informed clinical serendipity. 2 Its use spread quickly throughout the western world. Identification of its mechanism of action as dopamine receptor blockade 3 allowed industry laboratories to develop additional effective antidopaminergic compounds in a timely fashion. While the early literature reported 'cures,' it gradually became apparent that these drugs act to diminish psychotic symptoms, but not to cure the illness or to fully restore health. 4 Today, with both first-and second-generation antipsychotic drugs, the situation of persons with schizophrenia is vastly improved, but all still suffer considerable residual symptom burden and lifelong psychosocial impairments. In total, 10-20% of persons with the illness recover rather fully to approximate preillness levels of function (very good outcome) and another 15-20% are treatment resistant (highly troublesome outcome); the middle group suffers a range of ongoing mental impairments (cognitive, affective and psychotic impairments) despite medications.
The biggest impediment to progress in therapeutics is the lack of firm knowledge of disease pathophysiology. Without known molecular targets, therapeutics can advance only by serendipity, chance, or modifications of existing treatments. Hope for identifying the pivotal molecular targets for schizophrenia rests on the application of modern concepts and techniques of neuroscience to clearly diagnosed and characterized populations of persons with schizophrenia, supported by genetic information where relevant. Bold advances made in clinical assessment techniques, especially in brain imaging modalities, allow clinical scientists to make regional in vivo observations of brain structure, chemistry, and function in persons with the illness and compare outcome measures between ill and nonill populations and across phenotypes.
What is known with greatest certainty about schizophrenia is its clinical phenomenology with its behavioral presentation, cognitive characteristics, and electrophysiologic profile. This could be aptly called its clinical phenotype. The clinical picture is complex, and no one knows yet how the disease characteristics sort to individual phenotypes that are reflective of a single set of molecular target changes. Several aspects of the phenotype are distinctive and are presumed to be informative about schizophrenia pathophysiology: signs and symptoms, disease course, genetics, cognitive and task-activated brain activation patterns, postmortem tissue characteristics, and schizophrenia pharmacology will all contribute.
A Review
Symptoms and course Several meta-analyses of large schizophrenic populations have demonstrated the clustering of symptoms into at least three distinct symptom domains in schizophrenia: (1) positive symptoms, including hallucinations, delusions, and thought disorder, and paranoia; (2) cognitive dysfunction, especially in attention, working memory, and executive function; (3) negative symptoms with anhedonia, social withdrawal, and thought poverty. [5] [6] [7] [8] [9] [10] [11] Symptom clusters characteristically occur together; one cluster may predominate; one domain is not exclusive of another. Whether these symptom domains are multiple manifestations of a single disease pathophysiology or are each a partially independent disease construct remains unknown. However, heterogeneity is more often presumed about the illness, certainly with respect to etiology. There are therapeutic implications to heterogeneity: does one treatment exist for schizophrenia? Or are there several symptom or syndromespecific treatments for the illness? This question remains open, but taking clues from other illness, one would guess that several treatments will emerge.
The course of schizophrenia is life-long. Occasionally, the illness has a fast onset, is episodic in nature, has symptoms first occurring in late teen and early adult years, and shows satisfactory recovery between episodes. However, often other patterns of illness occur with an insidious onset, partial recovery, or a remarkable lack of recovery between episodes. 12, 13 In most affected persons, a profound deterioration in psychosocial function occurs within the first few years of the illness.
14 After the initial deteriorating years, the further course of illness settles at a low, flatter plateau. Surprisingly, symptoms can improve in later life after 50 years of age. The Vermont study found considerable heterogeneity in outcome in later life, including frank late improvers. 15, 16 These data are consistent with several other outcome studies, in Europe and the US, which report frequent good outcome in later years for individuals with schizophrenia 12, 13, 17, 18 even though divergent descriptions exist. 19 Whether elder years are merely less demanding periods or whether the normal aging process is therapeutic in the illness is not known. The disease course of schizophrenia can be easily distinguished from traditional neurodegenerative disorders where the course is progressively downhill (like Parkinson's disease or Alzheimer's dementia) and from traditional neurodevelopmental disorders (like mental retardation) where the course is low and steady from early years.
Prevalence
Certain epidemiologic factors have been regularly associated with a propensity toward the illness. Genetic predisposition is certain. 20, 21 Prevalence of schizophrenia is 1% in the general population, but approximately 8-10% in persons with a schizophrenic sibling, 12% in those with a schizophrenic parent, and 40-50% in identical twins. While a genetic constitution is influential, it does not inevitably result in the illness. Moreover, schizophrenia occurs without obvious family history. Both prenatal maternal illness during the second trimester and perinatal birth complications have been associated with schizophrenia as predisposing risk factors, and winter birth (summer conception) of the proband is associated with a small, but clear increase in risk for schizophrenia. Each risk factor confers a modest risk alone; genetics is the strongest risk factor. Possibly when factors occur together, these risks may be multiplicative. [22] [23] [24] [25] Moreover, the risk factors as a group suggest the importance of very early life events in the onset of an illness whose florid symptoms appear much later in life.
Cognition
Psychologic assessment of brain activity in schizophrenia might be expected to provide the highly relevant clues to abnormalities in the illness, because the core symptoms of schizophrenia are of a cognitive variety. Even though it is difficult to distinguish a schizophrenic from a normal brain by traditional anatomic or biochemical features, several psychologic and physiologic measures are able to provide distinguishing features between the two groups. Any ability to account for these differences with a compelling biologic explanation would certainly enable advances in our concepts of mechanisms in the illness.
Persons with schizophrenia perform poorly on most neuropsychological tests when compared to normals. This poor performance may be partly caused by symptoms of schizophrenia (eg, poor motivation or distraction from psychotic symptoms), but also negative effects of early onset of the illness and chronic institutionalization leading to the generalized deficits in these patients. 26 Several kinds of cognitive defects are particularly prominent in persons with the illness: working memory defects, attentional dysfunction, verbal and visual learning and memory, processing speed, and social learning. [27] [28] [29] [30] [31] [32] No cognitive domains are entirely spared, and deficits in performance are highly intercorrelated within persons. 33 However, schizophrenic subjects in many of the studies show a pattern of deficits, ruling out a complete lack of motivation as a factor in performance.
To date, neuropsychological characteristics of schizophrenia have not served to localize disease pathophysiology. For example, in schizophrenic persons, memory deficits for recurring digit occur that are consistent with temporo-hippocampal dysfunction. 27 Functions that are ascribed to frontal cortex are abnormal (for example, verbal fluency, spatial performance, pattern recognition), and long-term memory is affected. Besides, persons with schizophrenia also perform tasks poorly that require sustained attention or vigilance characteristically associated with the anterior cingulated. 34 Deficits in memory possibly involving hippocampus occur, including explicit memory, verbal memory, and working memory. 35, 36 Deficits in working memory may explain a part of the disorganization and functional deterioration observed in the illness, since the ability to hold information 'on-line' is critical for organizing future thoughts and actions in the context of the recent past. 37 These characteristics of cognition in schizophrenia suggest broad cortical dysfunction.
In addition to cognition, other manifestations of brain function are abnormal in schizophrenia. Several phenotypic expressions of provoked behaviors are known to be altered in the illness, including smooth and saccadic eye movements, 38, 39 prepulse inhibition, 40, 41 and P50 after auditory evoked potential. 42 These are spontaneous behaviors of the brain occurring in response to external cues that have known neural anatomies, and hence may be more direct reflections of neural pathology. 43, 44 The ability of some probands (60-70%) with schizophrenia to follow a smooth pendulum movement with their eyes is deficient. 45 Instead of describing smooth movements following a pendulum stimulus, some show jerky and irregular (delayed and catch-up movements) tracking patterns. Also, antisacade eye movements (those directed away from a stimulus) are also abnormal in persons with the illness. 45, 46 Prepulse inhibition (PPI) is a normal phenomena evident across all sensory modalities, where a small initial ('pre') stimulus decreases the electrophysiological response to a second higher intensity stimulus. In schizophrenia, many probands show abnormal PPI, as do unaffected family members. The neural systems influencing both oculomotor movements and PPI have been well described in the animal and are believed to be highly conserved in the human. 47, 48 P50 is an electrophysiologic measure produced when two equal auditory stimuli are presented 500 ms apart and their evoked potential is measured. Healthy persons show a reduced response (in amplitude) to the second signal; whereas persons with schizophrenia (estimated at 80%) show less or no suppression. Leonard et al 49 used an alteration in P50 suppression to describe a susceptibility locus on chromosome 15 in schizophrenia.
First-degree relatives of schizophrenic probands demonstrate many of these same cognitive and neurophysiologic deficits described in schizophrenia, even though these individuals do not manifest overt psychosis. [50] [51] [52] [53] [54] 39, 45 These deficits include predominately impairments in different dimensions of attention, language comprehension, verbal fluency, verbal memory, and spatial working memory, as well as abnormalities of eye tracking, PPI and P50. This has recently been documented by two comprehensive studies of schizophrenia relatives. 55, 56 Even after adjusting for IQ, measures of auditory attention, abstraction, and verbal memory differentiated relatives of persons with schizophrenia from the comparison groups. It is not clear whether the observed neurocognitive impairments in relatives are associated with schizophrenia spectrum personality symptoms. Some studies show that relatives meeting criteria for definite or probable schizotypal personality disorder have the most pronounced impairment, although not all cognitively impaired relatives met the diagnostic criteria for the probable or definite schizotypal personality disorder. 57, 58 Besides, other investigators [59] [60] [61] with diverse instruments (Wisconsin Card Sorting Test, Trail making, verbal fluency, Symbol Digit, and/or WAIS variables) also have documented cognitive change among relatives of a schizophrenic probands, independent of schizotypal diagnosis.
Clinical genetics and phenotypes
The heritability of schizophrenia is approximately 80%, but is not a simple pattern. There are thought to be multiple susceptibility genes, each of small effect along with influential epigenetic and environmental factors. Since schizophrenia has failed to show monogenetic forms and has no molecular or cellular markers, research has been slow. Nonetheless, replicated linkages to several chromosomal regions have been made, including to 8p, 22q, 2, 3, 5q, 6p, 11q, 13q, and 20p, 20 and there are several genes within these regions that have been associated with the illness, including neuregulin (NRG1), 62 dysbindin (DTNBP1), 63 G72, 64 D-amino-acid oxidase (DAAO), regulator of G protein-signaling-4 (RGS4), 65 proline dehydrogenase (ProDH), 66 and catecol-O-methyl transferase (COMT). 67, 68 Each of these genes codes for a protein that can be rationally linked with a purported illness mechanism 69 but no clear disease pathophysiology has yet emerged. The goal of confirming a susceptibility gene for schizophrenia is to acquire molecular information about disease mechanisms, which could potentially lead to a broader understanding of the illness and be a basis for novel treatment development.
Investigators argue that one important road block in identifying genetic correlates of schizophrenia is disease heterogeneity and/or diagnostic imprecision. Schizophrenia is an illness diagnosed entirely on phenomenology characteristics, and these may be an insufficient database to properly categorize homogeneous disease states. Therefore, investigators have been attempting to define more homogeneous phenotypes of schizophrenia in persons with the illness and in family members ('endophenotypes') and test these genetically. 21 The features most often used to develop phenotypes in the illness are neurocognitive characteristics, eye movements, PPI abnormalities, P50 changes, and human brain imaging features (reviewed in Gottes and Gould 21 ). While there has been only modest progress in this area, the orientation is just beginning to be applied and studies have only been recently initiated.
In vivo structural brain characteristics Early MRI studies reported a reduction in overall brain size, an increase in ventricular size, and variable cortical wasting in schizophrenia. [70] [71] [72] These reports confirmed and extended older literature using the computerized axial tomography (CAT) examination of schizophrenia that demonstrated ventricular enlargement. 73 The suspicion that a portion of these findings could be caused by antipsychotic treatment was raised by the results of a recent study showing haloperidol-associated increases in ventricular size and decreases in neocortical mass in first break schizophrenia over the first 3 months of treatment in a study where second-generation drug treatment produced none of these alterations (Lieberman, personal communication).
More recently, MRI studies have consistently reported a volume reduction in medial temporal cortical structures (hippocampus, amygdala, and parahippocampal gyrus). [74] [75] [76] [77] New analytic techniques for shape analysis show regional shape differences of hippocampus in schizophrenia. 78 The volume of the superior temporal gyrus may be reduced in schizophrenia, a change that correlates with the presence of hallucinations 75, 79 and with regional EEG changes. 80 Reports of other structural brain changes in schizophrenia have been less consistent. Increases in sulcal size are reported, along with decreases in gray matter volume and altered gyral patterns. 81 Even white matter volume increases have been seen. 77 Neocortical volume reductions have been reported in symptomatic subgroups of schizophrenic subjects, for example middle frontal cortex volume reduction in negative symptom schizophrenia. 82 The extent to which the overall volume of a brain structure reflects any internal pathology, especially if the pathology is subtle, is necessarily limited. Also, while positive MRI data identifies a brain area for further study, negative results do not rule out areas as pathologic. The use of functional imaging techniques has also been productive and will be reviewed below.
In vivo functional brain characteristics Early positron emission tomography (PET) studies reported relative hypometabolism in frontal cortex, a finding consistent with even earlier SPECT blood flow studies. 83, 84 Subsequent PET/FDG studies in schizophrenia produced inconsistent detection of frontal cortex hypometabolism, with some studies continuing to find it, 85 others reporting no change in the measure, 86 and still others finding frontal hypermetabolism. 87 These controversies now can be partially explained by two potential confounds: a neuroleptic effect and a skewed target population effect. Neuroleptics reduce cerebral metabolism in frontal cortex, 88 thus likely producing a confound in those early studies which compared neuroleptictreated schizophrenic persons with untreated normal controls. We also know that frontal cortical dysfunction is associated with deficit (negative) type schizophrenia, seemingly selectively. The composition of a patient group with neuroleptic-treated, deficit-type schizophrenics (which are often available for study) will skew the results. What component of the frontal hypometabolism is due to this confound and what to disease is difficult to say. Recently, we (reviewed in next section) and others have found evidence for limbic abnormalities in schizophrenia both at rest 86 and with cognitive challenge. [89] [90] [91] Heckers et al 92 found reduced hippocampal activation in schizophrenic subjects during a memory retrieval task of previously studied words. These findings complement other postmortem and structural imaging studies of abnormalities in medial temporal lobe structures of schizophrenics. 93, 94 In an attempt to relate rCBF to symptoms, Liddle et al 95 reported that negative symptoms were negatively associated with rCBF in left frontal cortex and left parietal areas. Hallucinations/delusions were positively associated with flow in the left parahippocampal gyrus and the left ventral striatum. Disorganization was associated with flow in anterior cingulate and mediodorsal thalamus. This study shows that different brain areas are differently involved in symptom manifestations in schizophrenia, perhaps either as a cause or effect of the disorder. Recently, a PET/H 2
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O study of hallucinating schizophrenic persons noted several CNS regions which activated in the subjects associated with hallucinations; these were the left and right thalamus, right putamen, left and right parahippocampal area, and right anterior cingulate. Cortical activations were present, but their cortical localizations were highly variable between the subjects and not significant in group analysis. 96 Further work from this group has shown that apomorphine (which is antipsychotic in schizophrenia, despite being a dopamine agonist) improves (that is, 'normalizes') the anterior cingulate blood flow of schizophrenic persons during verbal fluency task performance. 97 Abnormal functional connections between brain regions has been suggested as the cause of abnormal rCBF pattens seen in schizophrenia. 86, 98, 99 In studies of verbal fluency 100 and semantic processing, 101 a network analysis revealed a functional disconnection between the anterior cingulate and prefrontal regions of schizophrenic subjects. Frontal lobe functional connectivity was abnormal in the schizophrenic subjects even though they had significantly activated the regions and their behavior on the tasks was not impaired. These findings suggest that the abnormalities seen in the frontal lobes of schizophrenics may be a problem of integration across regions and not a specific regional abnormality.
Most recently in fMRI studies using cognitively demanding tasks, such as working memory tasks, the fMRI results are also diverse. Manoach et al 102, 103 used the Sternberg Item Recognition working memory paradigm which required the subjects to remember either two or five digits. Unlike many PET studies of working memory, they found an increase instead of a decrease in prefrontal rCBF in the schizophrenic volunteers as compared to the normal controls. Callicott et al 104 using the N-back task and Stevens et al 105 using the Word and Tone serial position task found decreases of rCBF in inferior frontal regions of schizophrenic subjects. The task performance of the schizophrenic subjects was significantly worse on the N-back and word serial position task, but was matched on the tone task. Research has shown that although rCBF increases in prefrontal regions with greater working memory demands, if working memory capacity is exceeded, the activation decreases. 106 Manoach suggests that the discrepant findings in schizophrenia may be explained by an overload of working memory in schizophrenic subjects for some tasks.
Characteristics of postmortem tissue
It is widely accepted that schizophrenia lacks identifiable neuropathologic lesions as occur in Parkinson's disease or Alzheimer's dementia. Certainly a more subtle tissue pathology must be expected. The possible confounds of tissue artefact, agonal state, chronic neuroleptic treatment, lifelongaltered mental state, and relevant demographic factors must always be considered in evaluating postmortem brain tissue studies. Many modern postmortem studies of pathology in schizophrenia tissue are available. 94, 107, 108 The application of multiple techniques in the face of incomplete guiding hypotheses has left the postmortem literature of schizophrenia very broad and often fragmented.
Several studies report a predominant expression of pathologic change in the illness in limbic cortex, but not necessarily a common neuropathologic feature. 94 Regions including the hippocampus, anterior cingulate cortex, thalamus, and mammillary bodies and their intimately associated cortical areas (entorhinal cortex) are regularly associated with abnormalities. Abnormalities of cell size, 109 cell number, 110 area, 111 neuronal organization, 112 gross structure, 113 and neurochemistry are cited. 93 The entorhinal cortex shows abnormalities of cellular organization in Layer II neurons. 114 It is interesting to recall that both structural changes on MRI 111 and (as will be described shortly) functional changes in PET 86 have targeted these same areas for interest in schizophrenia pathophysiology. The modest consistency of this localizing pathology, despite heterogeneity in concrete findings, is striking for the field across technically different studies.
However, limbic structures are not the only ones affected in postmortem studies. The neocortex especially frontal areas are associated with reports of cell or tissue loss: one study reported gray matter volume reductions, 115 two did not, 116, 117 and one reported increased neuronal packing in frontal cortex. 118 Goldberg found that schizophrenic twins performed more poorly than their unaffected identical co-twin on all performance measures. Specifically, abnormalities involved assessments of intelligence, memory, attention, verbal fluency, and pattern recognition. The nonill twins failed to differ in performance from unrelated normal control persons except for their reductions in 'logical memory' (Wechsler Scale) and in Trails A performance. 28 Akbarian et al 119 and Volk et al 120 report decreased expression of glutamic acid decarboxylase (GAD) mRNA in schizophrenic prefrontal cortex (PFC) without significant cell loss. It is thought that chiefly one of the GABA-containing cortical neurons may be reduced in schizophrenia, the chandelier cell. 121 The alterations in GABA system activity may be the basis of the already observed frontal hypometabolism repeatedly reported in functional imaging studies of the illness.
Several studies report cell loss and reduced tissue volume in thalamus, 122, 123 while others are negative. 124 For this cerebral region, it is possible that restricting analyses to symptom cognitive dysfunction domains could reduce outcome variability and provide sharper answers.
Regional studies of neocortical tissue have generated persuasive observations consistent with the idea that developmental mistakes in migratory pattern may be associated with schizophrenia. [125] [126] [127] [128] Specifically, Akbarian et al reported a reduction in nicotinamideadenine dinucleotide phosphate-diaphorase (NADPH)-staining neurons in the higher cortical layers of the schizophrenic dorsolateral PFC and an increase ('trailing') in these neurons in underlying white matter layers. 129 These findings are consistent with the idea of an impairment of neuronal migration of these particular cells into upper layers of frontal cortex during their critical developmental period (second trimester) in schizophrenia. Even earlier studies reported alterations in superficial cellular organization (for example, in Layer II) in entorhinal cortex, with Layer II cell 'trailing' in the lower cortical layers, again consistent with a neuronal migratory failure in this area of cortex. 114, 130, 131 Postmortem tissue studies in schizophrenia have not yet led us to a specific pathology or even to an exclusive region where pathology occurs. Certainly, reports of abnormalities in hippocampus and frontal cortex predominate. Taking into account that these are the areas most often examined, and that artifact abounds in all postmortem tissue studies, few firm conclusions can be drawn. It may be that postmortem tissue will be most useful for focused hypothesis testing.
Monoamine and glutamate system pharmacology Studies of biochemical markers of the dopamine system in schizophrenia was stimulated by the early pharmacologic observation that blockade of dopamine receptors in the brain reduces psychotic symptoms. 3 The hypothesis derived from this observation that dysfunction of the CNS dopaminergic system either in whole or in part accounts for psychosis in schizophrenia has been explored in all body fluids and in various conditions of rest and stimulation over the last half -century, 132, 133 with little real support except for the recent studies that show possible changes in DA release in acute illness phases. 134 More recently, because of its ubiquitous and prominent location in the CNS, and because the antiglutamatergic drugs phencyclidine (PCP) and ketamine cause a schizophrenic-like reaction in humans, the glutamate system and its interactions with dopamine have become a focus of study. Human brain imaging ligand binding studies done in vivo have been carried out with D2 dopamine receptor ligands to look for D2 dopamine receptor defect(s). An early study reported increases in D 2 -family receptors in neuroleptic-naive and neuroleptic-free schizophrenia, 135 and a later report suggested its presence in psychotic nonschizophrenics 136 ; but subsequent studies using various other D 2 ligands and replications with the initial ligand have been unable to replicate this finding. [137] [138] [139] [140] All schizophrenic individuals do not have increased D 2 -family receptors in the caudate-putamen, but an alteration in D 2 density may be characteristic of a subgroup of schizophrenic patients, perhaps those with a long duration of illness, or other special clinical characteristics. 141 The question remains whether D 2 -family receptors are elevated in a subgroup of schizophrenic patients or reflect a confound of medication effect in the initial report.
More recently, Laruelle et al 142 have measured dopamine release into the synapse using SPECT or PET imaging with low-affinity dopamine receptor ligands. He reported that persons with schizophrenia have an increased release of dopamine into the synapse during the acute phases of their illness in response to amphetamine challenge, compared to healthy controls. 143 Increased release seems not secondary to chronic antipsychotic treatment, since augmented release also occurs in first-episode patients and some family members. 134 This is one of the first replicated findings of dopaminergic dysfunction in schizophrenia.
While D2 dopamine receptors in striatum are associated with psychosis, the D1 dopamine receptors in frontal cortex have been more recently associated with the cognitive dysfunctions in the illness, especially working memory. 144, 145 Consistent with this idea, human brain imaging ligand studies suggest abnormalities in D1 receptor density in the frontal cortex of persons with schizophrenia. 146, 147 Support of this idea also derives from postmortem studies showing that dopaminergic transmission may be abnormal in parts of neocortex. 148, 149 This has lead to speculations that an agonist at the D1 receptor may be therapeutic in treating cognitive dysfunctions in schizophrenia. 150 The introduction of the new antipsychotic drugs over the last decade, and their generally superior action, has generated questions about the role of the serotonin system in the treatment and perhaps in the pathophysiology of the illness. Years ago, serotonin was hypothesized to be central to the pathophysiology of schizophrenia, because of the psychotomimetic actions of serotonergic drugs, like LSD. 151 Postmortem studies have failed to find consistent change in measures of the serotonin system in schizophrenia, including in receptors (in vivo and postmortem) or in metabolites. 152 Since serotonin has been shown to modify dopamine release in striatum, 153, 154 the augmented antipsychotic action of the new drugs may be mediated through modulation of dopamine release into the synapse. Indeed, drugs without any dopamine receptor affinity, but with only 5 HT2a receptor antagonism, do behave as antipsychotic drugs in animal models and show antipsychotic activity in humans. 155 Since the serotonin system has diverse receptors and functions, it is not surprising that this aspect is not yet fully explicated.
In support of the involvement of glutamate in schizophrenia, the early report of reduced glutamate levels in spinal fluid of schizophrenic patients was interpreted to suggest neuronal hypoglutamatergic function in the illness. 156 Although, this report was not consistently replicated, [157] [158] [159] (because the fraction of CSF glutamate considered to come from the transmitter pool is so small (o5%), the method was not considered sensitive enough to reliably find changes. However, Kornhuber's idea 156 of reduced glutamatergic transmission in schizophrenia has continued to capture the interest of the field. The demonstration of the antiglutamatergic action of phencyclidine (PCP), 160 a drug with potent psychotomimetic (perhaps schizophrenia-like) properties acting at the N-methyl-D-aspartate (NMDA) receptor, 161 provided further support. Putatively, PCP has its psychotomimetic properties secondary to its antiglutamatergic actions, with this being the mechanism of its endogenous psychosis. 162 The literature on glutamate in schizophrenia is suggestive, but not yet consistent in pointing to a specific defect. It is important to note that many assessments for the glutamate system in mammalian brain are early and lack sensitivity and selectivity. And, an understanding of the physiology of glutamatergic transmission is incomplete. Techniques and strategies to assess this function in schizophrenia are improving. Thus, technical and conceptual issues may be relevant to the failure to replicate findings. Perhaps the variety of disparate hippocampal glutamatergic findings themselves may be important as suggested by Ulas and Cotman, 163 leading to a final common blockade or inhibition of hippocampal efferent pathway activity in schizophrenia.
A Working hypothesis
For limbic cortex involvement in schizophrenia The development of a progressive tract of research, within a laboratory with studies built on previous findings, can demonstrate the development of a theme for disease pathophysiology. Studies in our laboratory over the last several years have been directed toward identifying the regions of functional pathology in schizophrenia that may contain critical molecular targets underlying schizophrenia, as a background for enabling the rational development of therapies for the illness. We have developed experiments based on the iterative strategy of starting with in vivo functional imaging studies in schizophrenia volunteers with unbiased regional analysis to identify regions of dysfunction in schizophrenia during various task conditions and drug treatments. Then, we have followed up these results using postmortem human tissue analysis within those identified regions to exhaustively study human protein markers of hypothesized systems.
It is easy to say that overall, the body of biological work in schizophrenia lacks replicated findings across laboratories, thus, making it particularly difficult to build a consistent story across all of the findings in the literature. Why this is the case is not clear, but most would ascribe it to differences in patient populations, in illness stages, in medication status, and in disease state, rather than in the technical measures used. In the research story described here, a modestly consistent line of findings have emerged: namely, the involvement of the limbic cortex in mediating the positive symptoms of schizophrenia. This may be because of several prospectively selected clinical characteristics of the studies: patients were relatively young; they were characteristically medication-free when studied in vivo; they were symptomatic with positive symptoms (negative symptom persons were excluded); and rigorous performance criteria were imposed for participation in the task-activated rCBF studies. These criteria all served to create a more homogenous (even though less generalized) set of patient participants and might have diminished variance on outcome measures enough to allow findings to emerge.
The early studies in this series of experiments asked the simple question: which brain areas are involved in positive symptom pathology in schizophrenia. Volunteers were medication-free for 4-8 weeks. PET scans with fluorodeoxyglucose (FDG) were performed with both patient and normal volunteers at rest. All comorbidities, other CNS drugs, and other diagnoses were excluded. Under these conditions, two brain areas showed glucose utilization (rCMRglu) differences between the normal and the schizophrenia groups, the anterior cingulate cortex (ACC) and the hippocampus (Hipp) ( Figure  1) . 86 A follow-up study of similar design tested the regional associations of positive symptoms and showed that as long as patient volunteers were medication-free, there was a significant association between rCMRglu in the limbic cortex (ACC plus Hipp) and the magnitude of positive symptoms in the illness ( Figure 2) ; this correlation did not obtain when patients were medicated or with other symptom domains. 164 These studies allowed us to speculate that it was the limbic cortex which is associated with the positive symptoms of the illness, while the PFC cortex may support negative and/or cognitive symptoms.
As a next experimental step, we put the schizophrenic brain to work on an effortful task and assessed the CNS functional activation patterns in schizophrenia. The schizophrenia volunteers had positive symptoms and were medication-free; and they were tested on an effortful auditory discrimination task involving learning, attention, and working memory. All of the volunteers were trained on the task with performance fixed to 80% correct. These performance features of the experimental design were necessary because the schizophrenia group, performing naively, did not perform anywhere near the level of the normal group, but could perform comparably with normals after training. Consequently, we Figure 1 A group of young, drug-free psychotic persons with schizophrenia were compared with a matched normal group. Of more than 40 ROIs compared between groups, only two, the anterior cingulate cortex (ACC) and the hippocampus (Hippo) differed between groups.
collected a relatively high-performing group of volunteers, not different on general neuropsychological measures from other groups of research subjects, but likely better performing on attention tasks and other measures of cognition than an average person with schizophrenia. In comparing these groups of volunteers, the only brain region whose function during the decision part of the task differed between the normals and schizophrenics was the ACC (Figure 3) . 165 In this comparison, the only schizophrenics who were in the data analysis were those whose performance was similar to the normals. When all of the patients were allowed into the analysis who performed the task at all levels (even though not up to the level of normals), then the area of defect extended to include the PFC along with the ACC suggesting that a performance confound might account for PFC hypofunction. It was not only that the ACC showed decreased rCBF in schizophrenia, but the rCBF was not correlated with the difficulty of the task. In normals, as the difficulty of the task increased, the ACC showed a linearly related increase in rCBF (Figure 4 ). This did not occur in the schizophrenia group, suggesting that the ACC may be cut off from the context of task performance.
The remaining defect that we identified in the rCBF of this schizophrenia group was an increase in hippocampal rCBF that occurred not only with the task, but across all the task conditions of Rest, Sensorimotor control (SMC), and Decision. The hippocampus, but only the anterior portion, showed an elevated rCBF ( Figure 5) . 166 That elevated rCBF was diminished toward normal with antipsychotic treatment (possibly 'normalized').
Having identified Hipp and ACC dysfunction in schizophrenic illness using in vivo functional brain imaging, we have now isolated these regions from postmortem tissue, schizophrenia, and control, and are analyzing basic histologic and neurochemical changes in the illness. Although a plethora of previous studies have reported a variety of changes, the reports have not used a consistent set of tissue and have not analyzed all parts of the regions within a single brain structure (eg, anterior vs posterior regions). Since functional change may be regionally specific, even within an organ, multiple segments must be assessed. Some of our early data, while showing no change in ionotropic glutamate receptor binding (AMPA, NMDA, or kainate), did show an alteration in NR 1 subunit mRNA and in NR 2B mRNA 93 . In preliminary analysis, we checked out this subunit expression in the anterior (abnormal rCBF) vs the posterior (normal rCBF) schizophrenia vs normal hippocampus. We have found differences, even in this preliminary analysis. No differences between anterior and posterior levels of NR 1 mRNA were obtained; NR 2B mRNA was higher in anterior Figure 2 In another group of persons with schizophrenia, all of whom were drug free, there was a significant correlation between the psychosis score (vertical axis) and the magnitude of glucose utilization in the ACC and Hippo (horizontal axis). This correlation disappeared when the same individuals were treated with antipsychotic medication. Figure 3 Persons with schizophrenia showed decreased rCBF in the ACC during the performance of an auditory discrimination task. than in posterior hippocampus, but these differences were similar across normal and schizophrenia tissue; but it was the NR 2A mRNA levels in entorhinal cortex and in the CA 3 subfield that were elevated in the anterior hippocampal sections but not in posterior parts, only in the schizophrenia tissue. Since the NR 1 / NR 2A type of NMDA receptor is now thought to be the predominant form at the cerebral synapse, these results suggest functional relevance. Although much work remains, we are now attempting to distinguish anterior from posterior hippocampal defects in schizophrenia as a clue to isolating and identifying the molecules possibly associated with generating psychosis in schizophrenia.
This tract of investigation suggests that in schizophrenia itself, the positive symptoms and possibly the cognitive dysfunction of the illness (including learning and memory disruptions and possibly attentional abnormalities) may emanate from the functional and chemical changes we have described in hippocampus and the downstream systems changes these primary lesions exert in ACC and PFC. We reported the limbic association with positive symptoms but have yet to study the cognitive illness manifestations and their possible association with limbic dysfunction. However, other laboratories associate frontal cortex dysfunction with the cognitive symptoms of illness, including memory, attentional, and executive function abnormalities. 121, 167 These data as a whole implicate the functional alteration in limbic cortex as potentially meaningful in the pathophysiology of the psychosis of schizophrenia. They suggest that the neural input from the hippocampus to its efferent structures, ACC and PFC, is disordered in the illness and may account for positive symptoms. However, the specific molecular mechanisms leading to the functional change still need to be identified. Still, with localization clues derived from rCBF studies, these molecular changes associated with putative surrogate psychosis markers (ie, altered rCBF) can be screened for involvement in the illness.
Conclusion
Schizophrenia continues to be an illness without known pathophysiology or etiology. However, clues to pathophysiology are emerging along with a meaningful anatomy. Furthermore, the need to sort these characteristics by reduced phenotypes in order to associate molecular change with functional expression is becoming clear. The phenotypes of schizophrenia, defined by symptoms, psychological, electrophysiologic, biochemical, or physiologic (ie, rCBF) characteristics are being proposed. The sorting of these phenotypes into biologically and pharmacologically meaningful groups is ongoing. The overall importance of this task lies in defining the molecular targets of the illness to facilitate rational drug discovery. Targeting the exact pathophysiology of schizophrenia for pharmacologic treatment could deliver substantial improvements in outcome to persons with schizophrenia.
